A Phase 2 interventional study of AND017 in Myelodysplastic Syndromes, sponsored by Kind Pharmaceuticals LLC. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-27.
Sponsored by Kind Pharmaceuticals LLC · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 117 studies in Myelodysplastic Syndromes with a site in China — 55 open to participants now, 62 under way, 7 of them phase 3. Myelodysplastic Syndromes · China.
Among the 117 studies in Myelodysplastic Syndromes with a site in China, this one is the 59th largest by planned enrollment of the 102 interventional ones that give a count, is one of 12 that started in 2025, is one of 31 in phase 2, reaches primary completion later than 30 of the 61 other live ones, and was the 72nd registered.
1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.
Browse Myelodysplastic Syndromes studies →55 of the 117 studies in Myelodysplastic Syndromes with a site in China are open now. Recruiting first, the newest first:
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18–70
Peking University People's Hospital · Sites in China
Ages 18–65
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Sites in China
Ages 18+
Fujian Medical University Union Hospital · Sites in China
Ages 14–60
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
117 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 40 · Phase 2 60 · Phase 3 21 · Phase 4 4
First in 2003; this study’s year is marked. 12 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 63 is above the median of 40 across 1,611 interventional studies indexed under Myelodysplastic Syndromes.
Median enrollment 76 across the 102 interventional studies, 250 across the 15 observational. Of the 27 that completed or were terminated, 9 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
55 of 117 have an industry lead sponsor. The 10 most frequent:
Kind Pharmaceuticals LLC is the lead sponsor of 11 studies on the registry; 7 are open to participants now.
Kind Pharmaceuticals LLC has 1 study filed under Myelodysplastic Syndromes — fewer than ten, so there is no comparison to draw.
13 of the studies in Myelodysplastic Syndromes with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04401748Phase 3AbbVieStudy Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | 2027-07 |
| NCT06304103Kind Pharmaceuticals LLCA Study of Efficacy and Safety of AND017 in Patients With Myelodysplastic Syndrome | 2026-12 |
| NCT04428489The First Affiliated Hospital of Soochow UniversityFollow-up Study of ICUS and CCUS Patients | 2026-12-31 |
| NCT07449286Peking University People's HospitalIFN-α in Relapse Prevention. | 2026-12-31 |
| NCT06378437Hangzhou GluBio Pharmaceutical Co., Ltd.A Study of GLB-001 in Patients With Myeloid Malignancies | 2026-12-31 |
Add all 13 to your calendar (.ics) → With an account.
Among the 117 studies in Myelodysplastic Syndromes with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2, multicenter, randomized, open-lable, dose ranging study to evaluate the efficacy and safety of AND017 for the treatment of anemia due to lower risk Myelodysplastic syndromes (MDS) in patients subjects who are Red blood cell (RBC) non-transfusion dependent (NTD) and low transfusion burden (LTB).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adequate liver function with:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: AND017
Drug: AND017
Drug: AND017
Administer AND017 once per day (QD)
Percentage of HI-E/RBC-TI responding subjects
* NTD cohort: non-transfused Hb levels ≥1.5 g/dL relative to baseline\* during any 8-week period from baseline to 24 weeks post-dose. * LTB-1 cohort: No transfusion during any 8-week period from baseline to 24 weeks post-dose. * LTB-2 cohort: No transfusions during any 8-week period from baseline to 24 weeks post-dose and untransfused Hb levels ≥1.5 g/dL. * Hb baseline is the average of the two lowest Hb over the 16 weeks prior to the first dose
Time frame: From baseline to up to Week 25
For changes in mean transfusion units throughout the treatment period compared to baseline (mean transfusion units 16 weeks prior to first dose)
For changes in mean transfusion units throughout the treatment period compared to baseline (mean transfusion units 16 weeks prior to first dose)
Time frame: Baseline, Week 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25
For LTB cohorts, the average time required to reach first transfusion independence throughout the treatment period
For LTB cohorts, the average time required to reach first transfusion independence throughout the treatment period
Time frame: Baseline, Week 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25
Levels of reticulocyte count at each visit and change from baseline
Levels of reticulocyte count at each visit and change from baseline
Time frame: Baseline, Week 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25
Levels of hematocrit at each visit and change from baseline
Levels of hematocrit at each visit and change from baseline
Time frame: Baseline, Week 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25
Levels of mean corpuscular volume at each visit and change from baseline
Levels of mean corpuscular volume at each visit and change from baseline
Time frame: Baseline, Week 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25
Levels of mean corpuscular hemoglobin at each visit and change from baseline
Levels of mean corpuscular hemoglobin at each visit and change from baseline
Time frame: Baseline, Week 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25
Mean level and change from baseline in non-transfused Hb at each visit throughout the treatment period and
Mean level and change from baseline in non-transfused Hb at each visit throughout the treatment period
Time frame: Baseline, Week 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25
Mean level and change from baseline in non-transfused Hb throughout the first 8 weeks of treatment
Mean level and change from baseline in non-transfused Hb throughout the first 8 weeks of treatment
Time frame: Baseline, Week 3, 5, 7, and 9
Percentage of visits in which non-transfused Hb was maintained in this range after reaching two consecutive increases of ≥1.5 g/dL and ≥1.0 g/dL from baseline, respectively, throughout the treatment period
Percentage of visits in which non-transfused Hb was maintained in this range after reaching two consecutive increases of ≥1.5 g/dL and ≥1.0 g/dL from baseline, respectively, throughout the treatment period
Time frame: Baseline, Week 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25
Mean time required after two consecutive increases in non-transfused Hb ≥1.5 g/dL and ≥1.0 g/dL from baseline, respectively, throughout the treatment period
Mean time required after two consecutive increases in non-transfused Hb ≥1.5 g/dL and ≥1.0 g/dL from baseline, respectively, throughout the treatment period
Time frame: Baseline, Week 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25
Started Mar 2025 (actual). Primary completion is estimated for Dec 2026, 21 months after the start.
Of 52 industry-sponsored phase 2 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's planned 21 months is below that.
Counting every sponsor, half of 279 studies reached it within 66 months; a quarter within 40 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AND017
Kind Pharmaceuticals LLC